Skip to main
LRMR
LRMR logo

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics Inc. is positioned for growth due to its innovative CPP technology platform and promising lead product candidate, CTI-1601, aimed at treating Friedreich's ataxia. Forecasted sales for nomlabofusp are expected to begin at $6 million in 2026 and reach $356 million by 2030, reflecting significant revenue potential as the product moves closer to market readiness. Additionally, positive interim data revealing increased FXN levels and validated mitochondrial activity in animal models supports a robust risk/benefit profile that could enhance investor confidence leading up to regulatory milestones and commercial launch.

Bears say

Larimar Therapeutics Inc, as a development-stage biotechnology company, struggles with consistent profitability and faces uncertainty regarding its path to profitability, which poses a significant burden on its stock performance. Compounding these challenges, the FDA's rejection of buccal/skin FXN as a surrogate endpoint hampers the company's regulatory advancements and raises concerns about the long-term viability of its lead product candidate, CTI-1601. Additionally, the potential need for invasive cardiac biopsies and high orphan drug pricing could lead to further commercialization and financing challenges, adding to the negative outlook on the company's stock.

LRMR has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 10 analysts, LRMR has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.